pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

412 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT776Endpoints580BioPharma Dive223onclive165Fierce Biotech54BioSpace52raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • <![CDATA[BRUIN CLL-321 Trial Impact and Treatment Selection]]>
    <![CDATA[Experts outline relapse workup in CLL, using PET-CT and biopsy for suspected Richter’s, plus resistance and TP53 testing to guide next therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Biomarker-Driven Treatment Decisions and Managing Progression After Frontline Immunotherapy]]>
    <![CDATA[Upfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.]]>
    onclive · 2mo ago↗ source
  • [Podcast] Closing the Distance in Cancer Care
    <figure><div><img src="https://imgproxy.divecdn.com/dY7Wm0PCubv9b4fcIzKfj5an0kT_H96KaWu7liYNw1Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9NY0tlc3Nvbl9Qb2RjYXN0XzEzNDZ4NzI5X…
← prev
page 11 of 17
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 2mo ago
↗ source
  • <![CDATA[Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer]]>
    <![CDATA[Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond]]>
    <![CDATA[Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[AUA and SUO Amend Advanced Prostate Cancer Guideline]]>
    <![CDATA[The AUA and SUO released the 2026 amendment to the Advanced Prostate Cancer Guideline.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma ]]>
    <![CDATA[Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma]]>
    <![CDATA[Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.]]>
    onclive · 2mo ago↗ source
  • FDA chief Marty Makary resigns from agency, ending tumultuous tenure
    <figure><div><img src="https://imgproxy.divecdn.com/lfiTfXKtJER0ScsazbccJFY15dK3uUIVJZ6JBQZD8TA/g:nowe:0:104/c:1024:578/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy…
    BioPharma Dive · 2mo ago↗ source
  • Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
    <figure><div><img src="https://imgproxy.divecdn.com/xFVDAUb89QQFVPrJL8faaWdXxcY16WqAOJqd9TV5Hi0/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzY5MDAzNjAwLmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk]]>
    <![CDATA[A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Grants Breakthrough Therapy Designation to Emi-Le for Adenoid Cystic Carcinoma]]>
    <![CDATA[Emi-Le received breakthrough therapy designation from the FDA for the treatment of patients with locally advanced, recurrent or metastatic ACC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA Demonstrates Manageable Safety and Early Efficacy mCRPC ]]>
    <![CDATA[[177Lu]Lu-D-Dan-Phe-PSMA showed early signals of safety and activity in mCRPC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Issues Warning Regarding Risk of Secondary Primary Malignancies With Tazemetostat in Follicular Lymphoma, Epithelioid Sarcoma ]]>
    <![CDATA[The FDA issued a warning about the risk of secondary primary malignancies associated with tazemetostat in epithelioid sarcoma and follicular lymphoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026]]>
    <![CDATA[We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.]]>
    onclive · 2mo ago↗ source
  • Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
    <figure><div><img src="https://imgproxy.divecdn.com/d3kyAOKiV4alroZs496u4_W_RA0u2QbwRQbzfwY4ALY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNjg5NTg1NDg3X3JmN…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Unmet Needs in Endometrial Cancer]]>
    <![CDATA[Important unmet needs remain in endometrial cancer even as antibody drug conjugates begin to expand the therapeutic armamentarium.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Mechanism and Clinical Role of TROP2-Directed ADCs]]>
    <![CDATA[In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper exp…
    onclive · 2mo ago↗ source
  • <![CDATA[Future Directions in Relapsed and Refractory Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Parikh on the Feasibility and Importance of Immunotherapy Trials in Anal Cancer ]]>
    <![CDATA[Aparna R. Parikh, MD, discusses how trials like PODIUM-303 are reshaping the treatment paradigm for squamous cell anal carcinomas. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing Strategies After Progression in Multiple Myeloma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Mutated NSCLC: Targeting MET-Driven Resistance in Second-Line Therapy]]>
    <![CDATA[In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung…
    onclive · 2mo ago↗ source
  • <![CDATA[Sequencing ADCs in Endometrial Cancer]]>
    <![CDATA[Sequencing therapy in recurrent endometrial cancer is becoming more complicated as immunotherapy moves earlier and antibody drug conjugates gain momentum.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Second Clinical Scenario - Progressive Disease Despite Hematocrit Control]]>
    <![CDATA[Polycythemia vera symptoms like fatigue and aquagenic itching signal active disease; experts urge objective tracking and tailored therapy beyond phlebotomy.]]>
    onclive · 2mo ago↗ source
  • A year after Vertex’s big launch, pain drug research faces a pivotal moment
    <p>Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?</p>
    BioPharma Dive · 2mo ago↗ source